- Home
- IMPP vs NERV Comparison
IMPP vs NERV Comparison
Compare IMPP & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMPP | NERV |
|---|---|---|
| Founded | 1981 | 2007 |
| Country | Greece | United States |
| Employees | 49 | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.4M | 210.1M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | IMPP | NERV |
|---|---|---|
| Price | $4.81 | $4.47 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $10.50 |
| AVG Volume (30 Days) | 278.1K | ★ 379.3K |
| Earning Date | 05-22-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,175,600.00 |
| Revenue This Year | $51.79 | N/A |
| Revenue Next Year | $6.97 | N/A |
| P/E Ratio | $3.68 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.90 | $1.76 |
| 52 Week High | $6.57 | $12.46 |
Technical Indicators
Market Signals| Indicator | IMPP | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 47.71 | 46.68 |
| Support Level | $4.70 | $3.80 |
| Resistance Level | $5.02 | $4.59 |
| Average True Range (ATR) | 0.19 | 0.39 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 53.72 | 36.27 |
Price Performance
Historical ComparisonAbout IMPP Imperial Petroleum Inc.
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.